Eagle Pharmaceuticals (NASDAQ:EGRX) Stock Rating Lowered by StockNews.com

Eagle Pharmaceuticals (NASDAQ:EGRX – Get Rating) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” rating in a report issued on Tuesday.

Separately, Piper Sandler dropped their price objective on shares of Eagle Pharmaceuticals from $41.00 to $31.00 in a research report on Tuesday.

Eagle Pharmaceuticals Stock Performance

NASDAQ EGRX opened at $25.62 on Tuesday. The company has a current ratio of 1.52, a quick ratio of 0.99 and a debt-to-equity ratio of 0.11. The firm’s fifty day moving average price is $30.48 and its two-hundred day moving average price is $31.00. Eagle Pharmaceuticals has a 1 year low of $23.87 and a 1 year high of $52.22. The firm has a market capitalization of $333.57 million, a P/E ratio of 13.34 and a beta of 0.92.

Hedge Funds Weigh In On Eagle Pharmaceuticals

Several large investors have recently modified their holdings of EGRX. Pacer Advisors Inc. acquired a new position in shares of Eagle Pharmaceuticals in the third quarter valued at about $1,564,000. Massachusetts Financial Services Co. MA grew its stake in shares of Eagle Pharmaceuticals by 36.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 18,914 shares of the specialty pharmaceutical company’s stock valued at $500,000 after acquiring an additional 5,065 shares in the last quarter. Alps Advisors Inc. acquired a new position in shares of Eagle Pharmaceuticals in the second quarter valued at about $335,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its stake in shares of Eagle Pharmaceuticals by 71.8% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 293,994 shares of the specialty pharmaceutical company’s stock valued at $13,062,000 after acquiring an additional 122,898 shares in the last quarter. Finally, Watershed Asset Management L.L.C. grew its stake in shares of Eagle Pharmaceuticals by 36.7% in the third quarter. Watershed Asset Management L.L.C. now owns 7,870 shares of the specialty pharmaceutical company’s stock valued at $208,000 after acquiring an additional 2,114 shares in the last quarter. 88.09% of the stock is owned by institutional investors.

Eagle Pharmaceuticals Company Profile

(Get Rating)

Eagle Pharmaceuticals, Inc is a biotechnology pharmaceutical company, which focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. Its products include RYANODEX, BENDEKA and BELRAPZO. The company was founded by Scott L.